It will also help to decrease medical visits, hospitalizations, and nursing home admission. In recent years, major therapeutic advances in osteoporosis treatment have been made as scientists gain a greater understanding of bone morphology and the underlying mechanisms causing osteoporosis.
Developing strategies to maintain and enhance bone density Exploring the roles of such factors as hormones, calciumvitamin D, drugs, and exercise on bone mass. Research Studies on Osteoporosis The following research studies have led to significant advances in understanding the causes of osteoporosisthe specific effects on the body, and potential new diagnostic, treatment, and prevention options: Identification of a gene essential for the formation of bone.
Through a convergence of efforts by investigators around the world, research has shown that normal skeletal development in both mice and humans requires two active copies of the gene Cbfa1. This discovery is expected to open up a number of exciting new research areas.
Discovery that estrogen causes "programmed cell death" in the cells responsible for degradation of bone osteoclasts. By paving the way for future assessment of whether drugs can also affect the programmed cell death of osteoclasts thereby making them potentially useful as bone-protecting treatmentsthis discovery represents an exciting link between basic research and tangible patient benefit.
Discovery of a collection of molecules created by researchers called peptidomimetics that successfully blocks part of the bone resorption process. This is the first clear indication that a particular synthetic antagonist may be effective in the prevention of osteoporosis.
The finding may hold promise for combating bone loss in women who cannot tolerate estrogen therapy. Patient-based research finding with clear implications for developing and targeting new preventive strategies.
A recent research study on elderly women who already had several spine fractures at the start of the study determined that they experienced the greatest health benefit from calcium supplementation both in terms of reducing the rate of new spine fractures and stopping bone loss.
A recent study supported by NIAMS National Institute of Arthritis and Musculoskeletal and Skin Diseases tested the usefulness of daily low-dose estrogen plus progesterone in women over age 65 and found that these women showed significant increases in spine, forearm, and total body bone mineral density.
This study provides proof that low-dose estrogen can be an effective preventive and therapeutic option. Study of osteoporotic fractures SOF. The development of risk-prediction models for osteoporotic fractures that incorporate clinical risk factors, along with bone mineral density measurements, is an important advance in identifying persons at greatest risk for fractures and for whom intervention measures may be suitable.
The SOF, a study of postmenopausal Caucasian women, led to the identification of 14 clinical risk factors. Possession of five or more of these factors greatly increased the risk of fracture in the women in the study.
Information regarding the diseases, physical states, medical treatments, and drugs that can lead to the development of secondary osteoporosis is now available to physicians. The information alerts physicians to the appropriate use of treatment, the monitoring of patients at risk, and, where possible, the use of intervention measures to prevent the development of osteoporosis.
For example, it is generally agreed that patients on glucocorticoid therapy for 2 months or longer and patients whose conditions place them at high risk for osteoporotic fractures should be considered for bone density measurement.
Screening in the general population. Because there is a lack of sufficient evidence regarding the cost-effectiveness of routine screening or the effectiveness of early initiation of preventive drugs, an individualized approach is recommended for testing for bone loss.Are you interested in volunteering for a research study or clinical trial?
There are many reasons why you may be interested in being a part of a research study or clinical trial. Treatment for Osteoporosis. Medication and Treatment Adherence; Calcium/Vitamin D; Nutrition; You may not hear much about clinical trials until your healthcare.
Osteoporosis is a disease where increased bone weakness increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the vertebrae in the spine, the bones of the forearm, and the hip.
Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress. The effect of treatment of osteoporosis on mortality in 10 studies included in the secondary analysis, grouped by individual agents.
The two alendronate studies were not included in the primary analysis because the treatment dose was 5 mg/d for part of the study, which is not the approved dose. C-reactive protein (CRP) a protein that is produced in the liver in response to r-bridal.com is a biomarker of inflammation that is strongly associated with the risk of cardiovascular events, such as myocardial infarction and stroke.
Calcification the process of deposition of calcium salts. In the formation of bone this is a normal condition. A new treatment for osteoporosis provides major improvements in bone density and more effective protection against fractures than the current standard treatment.
These are the findings of a study published in the New England Journal of Medicine (NEJM). The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis.